0.74
+0(+0.00%)
Currency In USD
| Previous Close | 0.74 |
| Open | 0.48 |
| Day High | 0.74 |
| Day Low | 0.41 |
| 52-Week High | 8.9 |
| 52-Week Low | 0.25 |
| Volume | 972 |
| Average Volume | 3,861 |
| Market Cap | 1.98M |
| PE | 0.1 |
| EPS | 7.42 |
| Moving Average 50 Days | 0.86 |
| Moving Average 200 Days | 3.04 |
| Change | 0 |
If you invested $1000 in Vaccinex, Inc. (VCNX) since IPO date, it would be worth $0.31 as of April 19, 2025 at a share price of $0.74. Whereas If you bought $1000 worth of Vaccinex, Inc. (VCNX) shares 5 years ago, it would be worth $0.93 as of April 19, 2025 at a share price of $0.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
GlobeNewswire Inc.
Mar 07, 2025 10:15 PM GMT
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
GlobeNewswire Inc.
Dec 17, 2024 2:00 PM GMT
ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astroglios
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
GlobeNewswire Inc.
Nov 07, 2024 1:30 PM GMT
Partnerships will employ Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discoveryROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pione
Data not available